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Association Between Apolipoprotein E
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Patients with Type 1 Diabetes Mellitus
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In tro duc ti on
Diabetes mellitus (DM) is a complex disorder characterized
by hyperglycemia. Cardiovascular disease is frequent in type 1
DM. The most important cause of morbidity and mortality in type
1 DM is atherosclerosis (1). 
It has recently been shown that ultrasonography is a powerful
non-invasive tool for evaluating early atherosclerotic lesions in
the carotid artery (2,3,4). Increased carotid artery intima-media
thickness (CA-IMT) is significantly related to cardiovascular risk
factors and to carotid plaque, which is a more advanced
atherosclerotic lesion. Increased CA-IMT  may be observed even
in adolescents with type 1 DM (5).
Apolipoprotein E (Apo E) polymorphism has been accused
as being the responsible factor for development of
atherosclerosis. Apo E plays a major role in lipid metabolism and
has a high affinity for low-density lipoprotein (LDL) receptors (6).
It has three common isoforms (E2, E3, and E4) encoded by three
alleles (e2, e3, e4) in exon 4 of the Apo E gene. Apo E3 is the
most common form (7).
The aim of our present study was to assess the
atherosclerosis indices and CA-IMT in patients with type 1 DM
and also to investigate the relationship between Apo E
polymorphism and these factors. Especially, we aimed to find
which Apo E polymorphism is associated with atherosclerosis.
ABS TRACT
Ob jec ti ve: The most important cause of morbidity and mortality in type 1
diabetes mellitus (DM) is atherosclerosis. Apolipoprotein E (Apo E)
polymorphism is accused of being the genetic risk factor for atherosclerosis.
The aim of the present study was to determine which Apo E polymorphism
was related to atherosclerosis in patients with type 1 DM.   
Methods: Seventy-four patients  with type 1 DM were enrolled in the study.
Age, diabetes duration, daily insulin dose, microalbuminuria, and major
cardiovascular risk factors including anthropometric and metabolic parameters
were assessed in each patient. Non-invasive ultrasonographic measurements
were also performed. For determination of Apo E genotype, DNA was extracted
from venous blood from all subjects using standard methods. Apo E genotyping
was performed using a PCR–restriction fragment-length polymorphism assay.
Results: Systolic blood pressure and carotid artery intima-media thickness
(CA-IMT) were increased in subjects with E4/E4 polymorphism. According
to univariate analysis, when adjusted for all risk factors, genotypes did not
differ for total cholesterol, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol and triglycerides (p>0.05). However, E3/E3, E3/E4
and E4/E4 genotypes were found to be associated with an increase in 
CA-IMT (p<0.001). 
Conclusions: Our results suggest that the polymorphism associated with
atherosclerosis in type1 DM is Apo E4/E4.   
Key words: Atherosclerosis, apolipoprotein E, carotid artery intima-media
thickness, type 1 diabetes
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This study was performed in the Pediatric Endocrinology
Department at Erciyes University School of Medicine. The study
was approved by the local ethics committee of Erciyes
University and was conducted in accordance with the guidelines
proposed in the Declaration of Helsinki. Signed informed
consent was obtained from the parents.
Seventy-four patients (38 female, 36 male) with type 1 DM
participated in this study. Sex, age, anthropometric
parameters, blood pressure (BP), lipid profiles, daily insulin
dose, urinary albumin excretion, glycated hemoglobin (HbA1c)
level, common carotid artery functions and Apo E genotype
were determined in each patient.
Patients under 19 years of age, with type 1 DM, using insulin
therapy, and who had been followed for at least 1 year were
planned to be included in the study; thus, 38 female and 36 male
patients aged between 8 and 18 were recruited. None of the
patients had diseases such as hypertension, hyperlipidemia and
other cardiovascular diseases known to affect the common
carotid artery functions, and no patient was under any
medication other than antidiabetic drugs. None of the  patients
had ever smoked. 
Twenty four-hour urine samples were collected and
analyzed for presence of albuminuria after excluding proteinuria
due to urinary tract infection. Microalbuminuria was defined as a
24-h urinary albumin excretion of >30 mg. A urinary albumin
excretion exceeding 300mg/24h in at least two urine samples
evaluated within a 12-week interval was accepted to indicate
clinical nephropathy. None of the patients were diagnosed to
have renal disease unrelated to diabetes during their follow-up.
Hyperlipidemia was defined as a serum lipid level higher
than the 95th percentile for age and sex. BP was measured with
a standard mercury sphygmomanometer after the subjects had
rested for at least 10 min. Subjects were considered as
hypertensive if their systolic BP and/or their diastolic BP were
above the 95th percentile for age and sex, or if they were
receiving antihypertensive treatment. Anthropometric
measurements were performed by the same clinician in all
subjects. Height was measured using a wall-mounted
stadiometer and weight was determined using a balance scale
with the subject dressed only in light underwear and wearing no
shoes. Body mass index (BMI) was calculated as the ratio of
weight (kg) to the square of height (m)2. Hip circumference and
waist circumference were measured and recorded.
Blood samples were collected after a minimum eight hours
of fasting. Serum lipid concentrations and urine microalbumin
levels were assayed using the Konelab 60i analyser (Konelab,
Espoo, Finland). Plasma HbA1c concentrations were assayed
by automated high-performance liquid chromatography
(reference rate <6%).
Determination of Apo E polymorphism 
To perform Apo E genotyping assays, venous blood was
collected from all subjects in sterile EDTA 4-mL tubes. Genomic
DNA was extracted from whole blood using High Pure PCR
Template Preparation kits (Roche Diagnostics, GmbH
Mannheim, Germany). Apo E polymorphism was determined by
quantitative real-time reverse transcription-polymerase chain
reaction, which is a well-established and validated method
(LightCycler Apo E Mutation Detection Kit; Roche Diagnostics)
(Ballerini et al 2002). A 265-bp fragment of Apo E gene was
amplified with specific primers from human genomic DNA. The
amplicon was detected by fluorescence using a pair of
hybridization probes. The hybridization probes were also used to
determine the genotype by performing melting curve analysis
after the amplification cycles were completed.
Common carotid artery ultrasonography
All examinations were done by the same sonographer, who
was blinded to the participant’s case status and risk factor
levels. High-resolution B-mode ultrasonography of the right
common carotid artery was performed with SSA-370A Power
Vision 6000 Digital Ultrasound System equipped with a 7.5
MHz linear transducer (Toshiba Corporation, Tokyo). Subjects
were kept in a quiet, dark, temperature-controlled room and
rested in supine position for about 15-20 minutes. They were
examined in the supine position with the head slightly
extended and turned slightly to the left. Longitudinal images of
the common carotid artery were obtained by combined B-
mode and color Doppler ultrasound examinations. IMT of the
posterior (far) wall of the common carotid artery was measured
with the electronic calipers of the machines, as described by
Pignoli et al (8). On a longitudinal, 2-dimensional ultrasound
image of the carotid artery, images of the posterior wall of the
carotid artery are displayed as 2 bright white lines separated
by a hypoechoic space. The distance between the leading
edge of the first bright line of the far wall and the leading edge
of the second bright line indicates the IMT. The IMT was
measured during end diastole. The IMT measurements were
performed on-line. The mean IMT was calculated by taking the
average value of three measurements obtained from the
common carotid artery; 20 mm below the carotid bulb.
Statistics
Data analysis was performed using SPSS for Windows 11.5
package program. Kolmogorov Smirnov test was used to
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distributed. Descriptive statistics for continuous measurement
variables were shown as mean±standard deviation or median
(interquartile width). Nominal variables were presented as
number of cases as well as in percentages (%).
Significance of difference in terms of averages was
evaluated between the groups. When the number of
independent groups was limited to two, the Student’s t-test
was used. The significance of the differences between more
than two groups was evaluated in the parametric one-way
analysis of variance (one-way ANOVA). Significance of
differences in terms of medians was evaluated between the
groups. When the number of independent groups was two,
the Mann-Whitney U-test was used. The significance of the
differences between more than two groups was evaluated
applying the nonparametric one-way ANOVA (Kruskal-
Wallis).  
In instances of significant results with the Kruskal-Wallis test,
nonparametric multiple comparison tests were used to identify
the conditions that caused the difference.  
Nominal variables were evaluated with Pearson's chi-
square test. Statistically significant correlations between
continuous variables were assessed by the Spearman
correlation test. All possible risk factors thought to influence
the atherosclerosis indicators were adjusted. The
multivariate linear regression analysis was applied to detect
any statistically significant difference between genotypes.
Regression coefficient for each variable was calculated with
95% confidence interval. LDL cholesterol, high-density
lipoprotein (HDL) cholesterol and CA-IMT variables were not
normally distributed and logarithmic transformation was
performed for the linear regression analysis.
A p-value of less than 0.05 was considered statistically
significant for the results.
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Tab le  1. Clinical findings according to genotypes
Variables E3/E3 E4/E4 E3/E4 E2/E3 p-value
Age (years) 14.2±2.2 15.2±1.8 14.5±2.2 13.7±2.7 0.476
Gender 0.235
Female 11 (52.4%) 5 (83.3%) 14 (53.8%) 8 (38.1%)
Male 10 (47.6%) 1 (16.7%) 12 (46.2%) 13 (61.9%)
BMI 20.1±2.9 22.1±2.0 20.8±3.0 19.0±2.6 0.060
Waist-to-hip ratio 0.8±0.0 0.8±0.0 0.8±0.0 0.8±0.0 0.116
Duration of diabetes (years) 4.0 (4.0) 4.3 (5.3) 6.0 (3.5) 5.0 (3.8) 0.061
Daily insulin dose (U/day) 1.0 (0.3) 1.2 (0.5) 0.9 (0.2) 1.0 (0.3) 0.608
BMI: body mass index
Tab le  2. Laboratory findings according to genotypes
Variables E3/E3 E4/E4 E3/E4 E2/E3 p-value
HbA1c (%) 10.1±3.1 11.0±2.0 9.5±1.8 10.1±2.4 0.523
Microalbuminuria (mg) 7.8 (9.5) 10.0 (15.2) 7.3 (14.9) 7.8 (12.5) 0.970
Systolic blood pressure (mm/Hg) 115.0 (5.0) 120.0 (3.8) 115.0 (10.0) 110.0 (10.0) 0.019
Diastolic blood pressure (mm/Hg) 70.0 (5.0) 70.0 (3.8) 70.0 (6.3) 70.0 (5.0) 0.665
Total Cholesterol (mg/dL) 145.1±26.8 141.0±18.9 160.0±26.8 147.9±21.3 0.132
Triglyceride (mg/dL) 95.0 (63.0) 85.5 (31.3) 97.5 (53.5) 70.0 (29.0) 0.037
HDL Cholesterol (mg/dL) 48.0 (30.0) 40.5 (35.5) 52.5 (21.3) 55.0 (12.5) 0.234
LDL Cholesterol (mg/dL) 66.1 (28.2) 78.0 (19.7) 85.6 (29.9) 68.8 (18.0) 0.089
CA-IMT (cm) 0.5 (0.0) 0.6 (0.1) 0.5 (0.0) 0.4 (0.0) <0.001
HbA1c: glycated hemoglobin, HDL: high-density lipoprotein, LDL: low-density lipoprotein, CA-IMT: carotid artery intima media thicknessResults
The clinical and laboratory characteristics and CA-IMT
measurements of the patients  according to Apo E genotypes
are shown in Tables 1 and 2.  Systolic BP, triglyceride level and
CA-IMT were significantly different between genotypes. Systolic
BP and CA-IMT were higher in E4/E4 genotype, while
triglyceride level was higher in E3/E4 genotype.
There were no significant differences in CA-IMT
measurements, total cholesterol, triglyceride and HDL levels
between girls and boys. The p-values were 0.106, 0.105, 0.799
and 0.559, respectively.
The correlations between clinical characteristics and total
cholesterol, HDL cholesterol, LDL cholesterol.
Correlation coefficients, significance levels between CA-IMT
measurement and clinical characteristics are shown in Table 3.
CA-IMT was positively correlated with age, BMI, waist-to-hip
ratio and systolic BP.
According to univariate analysis, when adjusting for all risk
factors, genotypes did not differ for total cholesterol, HDL
cholesterol, LDL cholesterol and triglycerides (p>0.05). However,
E3/E3, E3/E4 and E4/E4 genotypes were found to be associated
with increased CA-IMT (p<0.001).
Discussion
Type 1 DM is associated with a two- to fourfold higher risk
of coronary artery disease (9). The increase of cardiovascular
risk in this population cannot be explained only by traditional
risk factors.
Studies on potential gene polymorphisms that can directly
affect the development of atherosclerosis are rare (10). Apo E
gene polymorphism is thought to cause an alteration in
lipoprotein metabolism. Apo E-deficient mice have been
reported to develop severe dyslipidemia and atherosclerotic
lesions (11). The E4 allele has been found to be related with LDL-
cholesterol levels. However, the effects of Apo E polymorphism
on triglyceride and HDL cholesterol levels have not been
resolved (12).
Studies have shown that increased CA-IMT is a predictor of
atherosclerosis. Associations between Apo E alleles and
cardiovascular risk have also been reported (13,14). Wohlin et al
(15) found increased CA-IMT in Apo E4 homozygous genotype.
In the ARIC  and CUDAS studies, E4/E4-homozygous men were
reported to have a significantly increased CA-IMT (16,17). In the
Rotterdam study, men with the e4/e4 genotype had slightly, but
not significantly increased CA-IMT (18). These studies were
performed in elderly persons and only in men. To our
knowledge, there are no studies assessing the  relationship
between CA-IMT and Apo E polymorphism in children with type
1 DM. In our study, we found higher CA-IMT in the E4/E4
homozygous genotype subjects.
It has been reported that the E4 and E3 alleles increase
plasma cholesterol concentration, while E2 alleles have an
opposite effect  (3,19). It was also reported that subjects with
E4 allele had higher lipid levels, especially LDL cholesterol
levels (20). Tascilar et al (20) and Fernandez et al (21) showed
that the E4 allele was associated with elevated LDL
cholesterol. Bennet et al (22) reported that Apo E genotypes
were related to LDL levels and coronary risk. E2 carriers were
found to have 20% reduced coronary disease risk, while E4
carriers had increased risk. In this study, we found no
significant association between LDL cholesterol, HDL
cholesterol, total cholesterol and Apo E genotypes. Only
triglyceride levels were significantly different between Apo E
genotypes and higher in E3/E4 allele. We think that these
results may be associated with the smallness of our sample.
In some populations, a stronger association between Apo E
4 allele and coronary artery disease was described for men (23).
However, a meta-analysis study revealed that Apo E genotypes
were not related to gender (22). No gender difference was found
in the present study.
Type 1 DM is an important risk factor for the development
of cardiovascular diseases (24). Carotid artery stiffness and
IMT measured by ultrasonography are correlated with
atherosclerosis and cardiovascular diseases in patients with
type 1 DM (25). Several groups have demonstrated that
patients with type 1 DM have higher mean CA-IMT. Increased
CA-IMT in children with type 1 DM may be an early step in the
development of  atherosclerosis. Yavuz et al (26) and
Gunczler et al (27) found no increase of CA-IMT in children
with type 1 DM. However, Yamasaki et al (28) Jarvisalo et al
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Tab le  3. Correlation coefficients, significance levels between CA-IMT
measurements and clinical characteristics
Variables CA-IMT
rp
Age (years) 0.231 0.048
Duration of diabetes (years) 0.198 0.091
Daily insulin dose (U/day) 0.075 0.525
HbA1c (%) 0.042 0.725
Microalbuminuria (mg) 0.082 0.485
BMI 0.344 0.003
Waist-to-hip ratio 0.273 0.019
Systolic blood pressure (mm/Hg) 0.380 <0.001
Diastolic blood pressure (mm/Hg) 0.206 0.078
HbA1c: glycated hemoglobin, BMI: body mass index, CA-IMT: carotid artery intima media thickness(29) and Vastagh I et al (30) reported that CA-IMT values were
significantly higher in children with type 1 DM. Jarvisalo et al
(29) also showed that type 1 DM was an independent risk
factor for high CA-IMT. Similarly, we demonstrated increased
CA-IMT in type 1 DM previously (31,32).
It is known that familial hypercholesterolemia and
borderline hypertension are related to high IMT (29,33). Also,
BMI was reported to be correlated with CA-IMT (34).
Childhood obesity seems to contribute to the development
and progression of early atherosclerosis. Zhu et al (35) found
higher CA-IMT in obese Chinese school children. We also
found that CA-IMT positively correlated with BMI, waist-to-
hip ratio, and systolic BP in our study.
Our study demonstrates the association of Apo E4/E4
polymorphism with CA-IMT and coronary artery disease in type
1 diabetes patients and this association is independent of
anthropometric and metabolic measurements. Apo E4/E4 allele
might be the major genetic risk factor for increased CA-IMT and
atherosclerosis in children with type 1 DM.
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